BDBM513667 US11091495, Example 169::US11091495, Example 228::US11091495, Example 28::US11091495, Example 78::US11091495, Example 86::US11220509, Example 169::US11485738, Example 86
SMILES Cc1cc(-c2cnc(NCc3c4CCOc4ccc3F)n3cc(nc23)C#N)n(C)n1
InChI Key InChIKey=WUFADHRATSOXBZ-UHFFFAOYSA-N
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 13 hits for monomerid = 513667
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: >500nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 300nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:An aliquot of each serial dilution of test compound was added to deep 384 well plate using Acoustic Technology instrument (Echo 550, LabCyte) contain...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 300nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:An aliquot of each serial dilution of test compound was added to deep 384 well plate using Acoustic Technology instrument (Echo 550, LabCyte) contain...More data for this Ligand-Target Pair